bevacizumab,trifluridine tipiracil
roche,otsuka,taiho pharma
[]
congrats by new data from sunlight reported at #gi23: patients with previously treated mcrpc receiving ftd/tpi + bevacizumab experienced extended os compared to those receiving ftd/tpi (10.8 mo vs 7.5 mo) with no significant safety issues 
Especialista en Oncoloxia Médica do Servicio Galego de Saúde (SERGAS) // Medical Oncologist of Galician Public Health System MD PhD